These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9949286)

  • 1. Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission.
    Umesaki N; Tanaka T; Muso H; Kawamura N; Kanaoka Y; Honda K; Deguchi M; Ishiko O; Ogita S
    Gynecol Obstet Invest; 1999; 47(2):139-43. PubMed ID: 9949286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H; Hayata T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.
    Topuz E; Eralp Y; Saglam S; Saip P; Aydiner A; Berkman S; Yavuz E
    Gynecol Oncol; 2004 Jan; 92(1):147-51. PubMed ID: 14751150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
    Menczer J; Ben-Baruch G; Rizel S; Brenner H
    Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies of prognostic factor and chemotherapeutic effect of epithelial ovarian cancer using Cox's proportional hazard model].
    Umesaki N; Sugawa T; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2351-6. PubMed ID: 8259850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.
    Barakat RR; Almadrones L; Venkatraman ES; Aghajanian C; Brown C; Shapiro F; Curtin JP; Spriggs D
    Gynecol Oncol; 1998 Apr; 69(1):17-22. PubMed ID: 9570993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of intermittent CDDP therapy for improving long-term prognosis in patients with advanced ovarian cancer].
    Umesaki N; Yamamoto A; Nakano M; Matsumoto Y; Tsuda K; Kawabata M; Sugawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1623-30. PubMed ID: 1744459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
    Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
    J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma.
    Umesaki N; Tanaka T; Kawamura N; Miyama M; Ichimura T; Ogita S
    Oncol Rep; 1999; 6(5):1035-7. PubMed ID: 10425299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of chemotherapy on the prognosis of ovarian cancer].
    Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
    Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy.
    Amikura T; Aoki Y; Kase H; Watanabe M; Sato T; Fujita K; Kurata H; Tanaka K
    Int J Clin Oncol; 2002 Feb; 7(1):45-50. PubMed ID: 11942049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.